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Introduction:
Malignant
Hyperthermia
•

•

•

•

Malignant Hyperthermia
(MH) is a life-threatening
disease process that can
be fatal if untreated.
MH is an autosomal
dominant
pharmacogenetic
disorder (Smith et al.,
2018).
This disorder is often
precipitated by the use of
volatile anesthetics and
depolarizing muscle
relaxants.
Although MH is fairly
uncommon, it accounts
nearly 1% of all
anesthesia related deaths
(Bamaga et al., 2016).

Why Malignant
Hyperthermia?
•

•

•

MH can be caused by
medications frequently
administered by the
anesthesia team.
Anesthesia providers
and nurses are tasked
with early detection,
treatment, and clinical
monitoring for patients
who develop MH.
Vigilance along with
proper education and
training on this disease
process can help reduce
fatalities associated
with MH (Smith et al.,
2018).

Significance of Physiology

Pathophysiological Processes
Underlying
Pathophysiology

Signs & Symptoms
•

•

•

•

•

•

•

MH can present at any point during an
anesthesia case. MH can develop shortly
after giving the triggering medications and
can be seen up to one hour after the
discontinuation of these medications
(Rosenberg et al., 2015).
Although, MH can be seen during an
individuals first exposure to anesthesia, it
can often take up to three exposures before
MH is triggered (Rosenberg et al., 2015).
One of the early signs of MH is the
unexplained increase in end-tidal CO2
(ETCO2) with increased ventilation (Smith
et al., 2018).
Additional symptoms of MH include
tachycardia, dysrhythmias, skeletal muscle
rigidity, rapid rise in core body
temperature, and rhabdomyolysis (Smith et
al., 2018).
As MH progresses, later symptoms include
metabolic and respiratory acidosis,
hyperkalemia, myoglobinuria, and
increased levels of creatine kinase (CK)
(Smith et al., 2018).
If the symptoms of MH are untreated for
long enough, other pathologies such as
disseminated intravascular coagulation
and/or acute renal failure may occur (Smith
et al., 2018).
Another symptom of MH that is specific to
children is masseter muscle rigidity
(Rosenberg et al., 2015).

•

•

•

•

MH is a disease process that can be
potentiated by potent inhaled
anesthetic gases such as sevoflurane,
isoflurane, desflurane, halothane. MH
can also be caused by nondepolarizing muscle relaxants like
succinylcholine (Abdulrahman,
2020).
In MH, a defect or mutation exists in
the calcium channel termed the
ryanodine receptor (RyR1). This
channel is responsible for the
regulation and release of calcium
from the sarcoplasmic reticulum (SR)
into the cell Rosenberg et al., 2015).
By introducing these anesthetic
agents into individuals with this
defect, an uncontrolled release of
calcium from the SR into the cell can
result. This then causes a
hypermetabolic state with sustained
muscle contraction, rigidity, and
hyperthermia. (Dagestad & Hermann,
2017).
This hypermetabolic state results in
excessive consumption and depletion
of adenosine-tri phosphate (ATP)
which then leads to the failure of
membrane integrity and the release
of CK and potassium. (Rosenberg et
al., 2015).

•
•

•

MH is a rare genetic disorder and because of this it is not often
diagnosed until symptoms develop.
The “gold standard” test for the diagnosis of MH is the in vitro
contracture test (IVCT). This test is based the contracture of muscle
fibers when introduced to caffeine of halothane. An individual is
considered susceptible to MH when muscle fiber contracture results
from both caffeine and halothane. However, IVCT is expensive,
requires surgical intervention, and is only done at specialized testing
centers (Rosenberg et al., 2015).
Another option to determine susceptibility to MH is genetic testing.
While this can provide useful data, it may also have ramifications for
the future health of individuals and their immediate family
members. Genetic testing can also be disadvantageous regarding the
ability of a individuals to gain employment or access health and/or
life insurance, therefore, the previously mentioned IVCT is preferred
(Rosenberg et al., 2015).

Implications for
Nursing Care
•

•

•

•

•

A large part of the prevention of MH
comes in the preoperative assessment.
It is vital that all members of the
healthcare team ensure a thorough
assessment is completed (Rosenberg et
al., 2015).
In order to optimize outcomes from
patients diagnosed with MH it is
imperative that nursing staff in the OR
and PACU be diligent in monitoring the
patient’s condition.
Nursing must be knowledgeable in the
presentation of MH so subtle changes in
patient condition can be identified and
reported. This includes familiarity with
monitoring devices such as ETCO2,
pulse oximetry saturation (SpO2), and
core temperature monitoring systems.
Nursing must not only know how to use
this equipment, but know what values
are expected in different situations (Xu
et al., 2019).
Knowledge of treatment as well as how
to rapidly access different treatments
such as dantrolene is essential for
nursing staff.
Specific for anesthesia providers – a
knowledge of alternative treatment and
medications for MH susceptible patients
is imperative.

Conclusions
•

•

•

•

•

•

MH is a rare genetic disorder
and a complications of
anesthesia with an incidence
of only 1:10,000 cases.
However, once MH begins its
rapid progression can cause
multiple organ failure leading
to death (Pan et al., 2016).
MH is a serious complication
that healthcare providers
must have a thorough
understanding of.
Hyperthermia in MH can
measured with a core
temperature increase of 1-2
degrees Celsius every 5
minutes (Rosenberg et al.,
2015).
Rapid detection and treatment
is the key to decreasing
mortality related to MH.
Children, younger adults, and
males are at an increased risk
for MH (Rosenberg et al.,
2015).
Dantrolene works by
decreasing RyR1 channel
activity and is imperative in
treating MH (Rosenberg et al.,
2015).
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Treatment
•
•

•

•
•
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Rapid treatment of MH is essential in preventing adverse outcomes
pertaining to MH. It is suggested that treatment be initiated within
3-7 minutes from the time of onset (Dagestad & Hermann, 2017).
After the discontinuation of provoking anesthetic agents, dantrolene
can be administered to treat MH. Dantrolene is a direct-acting
skeletal muscle relaxant that interferes with calcium release to help
stop skeletal muscle contraction (Dagestad & Hermann, 2017).
Dantrolene is administered intravenously with a maximum dose of
10mg/kg. A maintenance dose then recommended 48 hours from
the time of the last MH related symptom (Dagestad & Hermann,
2017).
Other treatments for MH are symptomatic and include ensuring the
patient is normothermic.
In addition to the initial treatments listed above, other therapies
such as extracorporeal membrane oxygenation (ECMO) and
continuous renal-replacement therapy (CRRT) may be beneficial in
more severe cases (Huh et al., 2017).
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